R & D

Mebs-Ig is an integrated open technology platform for building "multifunctional" bispecific antibody and building a new example of bispecific antibody, multiple specific antibodies. That is to make full use of and adjust the characteristics of each functional area and different modules of the antibody, and avoid the defects of some common bispecific antibody platforms, and to build the optimal "multifunctional" bispecific antibody. The bispecific antibody and bispecific antibody-drug conjugates developed by Combio using the Mebs-Ig technology platform are progressing smoothly and has been gradually applied for clinical research.